
John H Rex

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8743974/publications.pdf Version: 2024-02-01



ΙΟΗΝ Η Ρεγ

#	Article	IF	CITATIONS
1	Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020. Clinical Infectious Diseases, 2022, 74, 1183-1190.	2.9	15
2	Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0199121.	1.4	103
3	Antibacterial R&D at a Crossroads: We've Pushed as Hard as We Can … Now We Need to Start Pulling!. Clinical Infectious Diseases, 2021, 73, e4451-e4453.	2.9	11
4	Antibiotic development — economic, regulatory and societal challenges. Nature Reviews Microbiology, 2020, 18, 267-274.	13.6	218
5	Critical analysis of antibacterial agents in clinical development. Nature Reviews Microbiology, 2020, 18, 286-298.	13.6	204
6	Designing development programs for non-traditional antibacterial agents. Nature Communications, 2019, 10, 3416.	5.8	46
7	Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infectious Diseases, The, 2019, 19, e40-e50.	4.6	161
8	Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. Clinical Infectious Diseases, 2017, 65, 141-146.	2.9	56
9	Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks. Clinical Infectious Diseases, 2016, 63, S57-S59.	2.9	28
10	Alternatives to antibiotics—a pipeline portfolio review. Lancet Infectious Diseases, The, 2016, 16, 239-251.	4.6	720
11	Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infectious Diseases, The, 2016, 16, 500-505.	4.6	86
12	The evolution of the regulatory framework for antibacterial agents. Annals of the New York Academy of Sciences, 2014, 1323, 11-21.	1.8	30
13	Addressing the need for new antibacterials – Authors' reply. Lancet Infectious Diseases, The, 2013, 13, 834-835.	4.6	0
14	A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infectious Diseases, The, 2013, 13, 269-275.	4.6	111